Get the latest news, insights, and market updates on GOSS (Gossamer Bio, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Gossamer Bio, Inc. (GOSS) Stock Jumps 18% on FDA Updates and Seralutinib Progress
In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Gossamer Bio, Inc. is one of them. Gossamer Bio, Inc. (NASDAQ:GOSS) is a late-stage clinical biopharmaceutical company focused on developing and commercializing seralutinib, an inhaled small molecule therapy for pulmonary arterial hypertension (PAH) and […] Sep 23, 2025 - $GOSS
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025
SAN DIEGO, September 22, 2025--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that five scientific presentations related to seralutinib will be presented at the European Respiratory Society (ERS) Congress 2025, which takes place from September 27th th Sep 22, 2025 - $GOSS
Gossamer Bio (GOSS): Assessing Valuation After Encouraging Phase 2 Data and Analyst Optimism
Recent Data and Market Reaction: Can Gossamer Bio Deliver on Growth Hopes? If you have been eyeing Gossamer Bio (GOSS), this week’s developments might help you make a call. The company announced sustained clinical improvements from its Phase 2 TORREY trial for seralutinib, its lead therapy for pulmonary arterial hypertension. Not only did this reaffirm high hopes for the pipeline, but ongoing news about regulatory milestones and upcoming Phase 3 plans has given investors a reason to... Sep 15, 2025 - $GOSS
Gossamer Bio (GOSS) Is Up 17.7% After Seralutinib Gains Key FDA Support and Clinical Progress
In recent days, Gossamer Bio announced promising advancements for its lead candidate seralutinib, including new FDA designations and positive clinical progress targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension linked with interstitial lung disease (PH-ILD). An interesting takeaway is that Gossamer Bio’s intensified focus on lung-related conditions was underscored at recent investor conferences, highlighting its intent to compete for a substantial share of the PAH and... Sep 13, 2025 - $GOSS
Piper Sandler Reiterates Buy as Seralutinib Momentum Boosts Gossamer (GOSS) Multibagger Case
Gossamer Bio Inc. (NASDAQ:GOSS) is one of the best multibagger stocks to invest in right now. The company’s focus lies on its lead asset, Seralutinib, which targets pulmonary arterial hypertension (PAH), a severe condition with limited treatment options. Investor enthusiasm for the stock has grown markedly this year. It was trading around $1 at the start […] Sep 11, 2025 - $GOSS
Gossamer Bio to Present at Upcoming Investor Conferences
SAN DIEGO, August 29, 2025--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the following investor conferences in September. Aug 29, 2025 - $GOSS
H.C. Wainwright and Leerink Partners Reiterate ‘Buy’ Ratings on Gossamer Bio, Inc. (GOSS)
With significant hedge fund interest and a share price under $10, Gossamer Bio, Inc. (NASDAQ:GOSS) secures a spot on our list of the 11 Best Single Digit Stocks to Buy According to Hedge Funds. On August 7, 2025, H.C. Wainwright reiterated its ‘Buy’ rating on Gossamer Bio, Inc. (NASDAQ:GOSS) with a $10 price target. The […] Aug 19, 2025 - $GOSS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple